The economic value of treating OSA with PAP therapy
By reducing acute care costs and improving management of high-cost comorbidities, PAP therapy offers a compelling opportunity to reduce total cost of care.
Immediate action is needed by multiple sleep stakeholders to ensure the future burden of OSA can be clinically managed by sleep specialists and primary care providers (PCPs)
The value of clinical trial and real-world data together
RWE with RCTs blends theory with practice to increase patient representation and identify long-term trends, enhancing the ability to advance patient care.
